• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两名接受X连锁重症联合免疫缺陷(SCID-X1)基因治疗的患者中与LMO2相关的克隆性T细胞增殖。

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

作者信息

Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack M P, Wulffraat N, Leboulch P, Lim A, Osborne C S, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen J I, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva L E, Wissler M, Prinz C, Rabbitts T H, Le Deist F, Fischer A, Cavazzana-Calvo M

机构信息

INSERM Unit 429, Cedex 15, France.

出版信息

Science. 2003 Oct 17;302(5644):415-9. doi: 10.1126/science.1088547.

DOI:10.1126/science.1088547
PMID:14564000
Abstract

We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1, also known as gamma chain (gamma(c)) deficiency] in 9 out of 10 patients by retrovirus-mediated gamma(c) gene transfer into autologous CD34 bone marrow cells. However, almost 3 years after gene therapy, uncontrolled exponential clonal proliferation of mature T cells (with gammadelta+ or alphabeta+ T cell receptors) has occurred in the two youngest patients. Both patients' clones showed retrovirus vector integration in proximity to the LMO2 proto-oncogene promoter, leading to aberrant transcription and expression of LMO2. Thus, retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter.

摘要

我们之前已经证明,通过逆转录病毒介导的γ(c)基因转移至自体CD34骨髓细胞,10名X连锁严重联合免疫缺陷症(SCID-X1,也称为γ链缺乏症)患者中有9名得到了纠正。然而,在基因治疗近3年后,两名最年轻的患者出现了成熟T细胞(具有γδ+或αβ+ T细胞受体)不受控制的指数级克隆增殖。两名患者的克隆均显示逆转录病毒载体整合在LMO2原癌基因启动子附近,导致LMO2异常转录和表达。因此,逆转录病毒载体插入可引发频率意外的失控癌前细胞增殖,最有可能是由LMO2基因启动子上的逆转录病毒增强子活性驱动的。

相似文献

1
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.两名接受X连锁重症联合免疫缺陷(SCID-X1)基因治疗的患者中与LMO2相关的克隆性T细胞增殖。
Science. 2003 Oct 17;302(5644):415-9. doi: 10.1126/science.1088547.
2
Medicine. Gene therapy--new challenges ahead.医学。基因治疗——前方新挑战。
Science. 2003 Oct 17;302(5644):400-1. doi: 10.1126/science.1091258.
3
Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.X连锁重症联合免疫缺陷病基因治疗后T细胞癌基因LMO2的激活。
N Engl J Med. 2004 Feb 26;350(9):913-22. doi: 10.1056/NEJMra032207.
4
Gene therapy resumes.基因治疗得以恢复。
Nat Rev Cancer. 2002 Nov;2(11):813. doi: 10.1038/nrc943.
5
Genotoxicity of retroviral integration in hematopoietic cells.逆转录病毒整合在造血细胞中的基因毒性。
Mol Ther. 2006 Jun;13(6):1031-49. doi: 10.1016/j.ymthe.2006.03.001. Epub 2006 Apr 19.
6
Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.LMO2而非IL2Rγ的异位逆转录病毒表达会阻断CD34+细胞向人T细胞的发育:对基因治疗中白血病发生的启示。
Leukemia. 2007 Apr;21(4):754-63. doi: 10.1038/sj.leu.2404563. Epub 2007 Feb 1.
7
Gene therapy insertional mutagenesis insights.基因治疗插入诱变见解。
Science. 2004 Jan 16;303(5656):333. doi: 10.1126/science.1091667.
8
Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.在X连锁严重联合免疫缺陷小鼠模型中,比较五种含有人类白细胞介素-2受体γ链基因的逆转录病毒载体恢复T和B淋巴细胞的能力。
Mol Ther. 2001 Apr;3(4):565-73. doi: 10.1006/mthe.2001.0292.
9
[Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].[重症联合免疫缺陷病的基因治疗:有效性和安全性问题的原理证明。基因治疗、原发性免疫缺陷、逆转录病毒、慢病毒、基因组]
Bull Acad Natl Med. 2005 May;189(5):779-85; discussion 786-8.
10
Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.通过体外基因疗法对X连锁重症联合免疫缺陷进行持续矫正。
N Engl J Med. 2002 Apr 18;346(16):1185-93. doi: 10.1056/NEJMoa012616.

引用本文的文献

1
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.推进基因编辑疗法:针对多种疾病的临床试验和创新递送系统
Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9.
2
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.基因治疗时代:慢病毒载体及其假型化的进展
Viruses. 2025 Jul 24;17(8):1036. doi: 10.3390/v17081036.
3
Mapping Hematopoietic Fate after Transplantation.移植后造血命运图谱
Stem Cell Rev Rep. 2025 Aug 20. doi: 10.1007/s12015-025-10946-0.
4
Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up.细胞与基因治疗中的药物警戒:风险管理与长期随访中不断演变的挑战
Drug Saf. 2025 Aug 9. doi: 10.1007/s40264-025-01596-9.
5
InGeTox: a human-based in vitro platform to evaluate lentivirus/host interactions that contribute to genotoxicity.InGeTox:一个基于人体的体外平台,用于评估导致基因毒性的慢病毒/宿主相互作用。
Gene Ther. 2025 Jul 15. doi: 10.1038/s41434-025-00550-9.
6
CRISPR-based therapeutic genome editing for inherited blood disorders.基于CRISPR的遗传性血液疾病治疗性基因组编辑
Nat Rev Drug Discov. 2025 Jul 14. doi: 10.1038/s41573-025-01236-y.
7
In vitro HIV DNA integration in STAT3 drives T cell persistence-A model of HIV-associated T cell lymphoma.体外HIV DNA整合入STAT3驱动T细胞持续存在——一种HIV相关T细胞淋巴瘤的模型
PLoS Pathog. 2025 Jul 8;21(7):e1013087. doi: 10.1371/journal.ppat.1013087. eCollection 2025 Jul.
8
Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years.应对原发性免疫缺陷病领域的变革:把握未来十年的机遇并预见威胁
Front Immunol. 2025 Jun 17;16:1596971. doi: 10.3389/fimmu.2025.1596971. eCollection 2025.
9
Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination.用于艾滋病毒预防和控制的生物医学干预措施:超越疫苗接种
Viruses. 2025 May 26;17(6):756. doi: 10.3390/v17060756.
10
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.基于造血干细胞的抗HIV-1基因疗法,带有安全杀灭开关以抵御和对抗HIV-1感染。
Mol Ther Methods Clin Dev. 2025 May 15;33(2):101486. doi: 10.1016/j.omtm.2025.101486. eCollection 2025 Jun 12.